OBJECTIVES:

To evaluate of the cost - effectiveness of two budesonide dry powder inhalers, which included Easyhaler and Turbuhaler devices in adult and adolescent patients in Russian Federation. The patients were represented by persons older than 12 years of age with asthmatic disease, who had no experiences with inhaler usage (inhaler naive).

METHODS:

Information search was conducted in the public domain. Pharmacoeconomic analysis methods: cost – effectiveness analysis was performed. The study had a time horizon of 1 year. The evaluation of therapy effectiveness was based on quality-adjusted life years (QALY) criteria. The QALY was calculated of relationship between quality of life and compliance. Utility data were received from published literature. The direct cost of the various medications per patient was calculated. Cost analysis was conducted on the cost of basic pharmacotherapy, compensation costs for treatment of exacerbations, compensation costs for side effects and adverse events. Exacerbation defined as any of the following: hospital visits, primary care physician visits and visits to healthcare professional

RESULTS:

Results showed that budesonide via Easyhaler had a total direct cost per adult/ adolescent patient with asthma amounted to EUR 985 per year (versus EUR 1,113 to the Turbuhaler group) and cost saving prepared by of EUR 161 per QALY versus budesonide via Turbuhaler.

CONCLUSIONS:

Treatment of asthma in adult/ adolescent patients of budesonide via Easyhaler was a dominant by compare to budesonide via Turbuhaler in Russian Federation.